a nonsignificant trendP =0.070
For the NIHSS 16 cutoff, antiplatelet therapy at discharge showed a nonsignificant trend toward lower recurrence risk (HR, 0.73 [95% CI, 0.52–1.03]; P =0.070; OR, 0.72 [95% CI, 0.50–1.03]; P =0.070).
For the NIHSS 16 cutoff, antiplatelet therapy at discharge showed a nonsignificant trend toward lower recurrence risk (HR, 0.73 [95% CI, 0.52–1.03]; P =0.070; OR, 0.72 [95% CI, 0.50–1.03]; P =0.070).